In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BMS to test Opdivo combined with Nektar’s NKTR214; terminated and superseded by new deal

Executive Summary

Bristol-Myers Squibb Co. agreed to evaluate a combination of its Opdivo (nivolumab) with Nektar Therapeutics’ NKTR214 in Phase I/II trials in five tumor types and seven indications. Nektar retains worldwide commercialization rights to NKTR214.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Immuno-Oncology
    • Large Molecule
      • Antibodies
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)
    • Trial Collaborations
    • R&D (No Licensing)

Related Companies